Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00223925
Status:
COMPLETED
Last Update Posted:
2021-05-13
First Post:
2005-09-13
Brief Title:
Maribavir for Prevention of CMV After Stem Cell Transplants
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Dose-ranging Study to Assess the Safety Tolerability and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cytomegalovirus CMV infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None